|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004153,
umls-concept:C0011849,
umls-concept:C0014257,
umls-concept:C0078058,
umls-concept:C0277785,
umls-concept:C0439849,
umls-concept:C0533670,
umls-concept:C0540511,
umls-concept:C1256770,
umls-concept:C1883709,
umls-concept:C2587213
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-4-12
|
|
pubmed:abstractText |
microvascular complications in diabetes identify those at risk of cardiovascular disease (CVD), suggesting a link between abnormal neovascularisation and CVD. This may be related to high plasma vascular endothelial growth factor (VEGF). We hypothesised increased angiopoietins (Ang)-1 and -2 in patients with diabetes that are related to VEGF, medium-term glycaemic control, endothelial damage/dysfunction and atherosclerosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0021-9150
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
180
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
113-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15823283-Aged,
pubmed-meshheading:15823283-Angiopoietin-1,
pubmed-meshheading:15823283-Angiopoietin-2,
pubmed-meshheading:15823283-Carotid Artery Diseases,
pubmed-meshheading:15823283-Cross-Sectional Studies,
pubmed-meshheading:15823283-Diabetes Mellitus, Type 2,
pubmed-meshheading:15823283-Endothelium, Vascular,
pubmed-meshheading:15823283-Epidermal Growth Factor,
pubmed-meshheading:15823283-Female,
pubmed-meshheading:15823283-Humans,
pubmed-meshheading:15823283-Hyperglycemia,
pubmed-meshheading:15823283-Male,
pubmed-meshheading:15823283-Middle Aged,
pubmed-meshheading:15823283-Multivariate Analysis,
pubmed-meshheading:15823283-Vascular Endothelial Growth Factor A,
pubmed-meshheading:15823283-von Willebrand Factor
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis.
|
|
pubmed:affiliation |
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
